Skip to main content
. Author manuscript; available in PMC: 2017 Oct 3.
Published in final edited form as: Oncogene. 2017 Apr 3;36(32):4610–4618. doi: 10.1038/onc.2017.83

Figure 6. Suppression of HBEGF expression in vitro and in vivo.

Figure 6

(a) Western blot of isogenic astrocytes infected with TRE-HBEGF and/or tet-off with or without 2 μg/ml of doxycycline for 72 h. (b) Kaplan-Meier survival analysis of tumor-bearing Nestin-TVA;Ink4a/Arf lox/lox injected with RCAN-TRE-HBEGF, RCAS-tet-off, and RCAS-Cre that were not treated (n = 9, round dash) and treated starting at 21 days of age (n = 21, solid line). Statistical significance is shown by the following key: * P < 0.05, ** P < 0.005, *** P < 0.0005. (c) Same as in B but for Nestin-TVA;Ptenlox/lox injected with RCAN-TRE-HBEGF, RCAS-tet-off, and RCAS-Cre (n = 11, round dash) (n=21, solid line). Statistical significance is shown by the following key: * P < 0.05, ** P < 0.005, *** P < 0.0005. For treatment studies, diet containing 625 mg/kg of doxycycline was used (Envigo TD.08434).